Please login to the form below

Not currently logged in
Email:
Password:

Prostate cancer deaths double in men with faulty gene

Rencently published findings show that men with prostate cancer caused by a faulty BRCA2 gene are twice as likely to die from the disease as men with a faulty BRCA1 gene

Cancer Research UK has published findings which show that men with prostate cancer caused by a faulty BRCA2 gene are twice as likely to die from the disease as men with a faulty BRCA1 gene.

Prostate cancer takes the lives of around 10,000 men in the UK each year. With around 35,000 new cases diagnosed each year, and a one in 14 lifetime risk of developing it, prostate cancer is the most common cancer in men in the UK.

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: "Although only a very small percentage of men with prostate cancer will carry a faulty BRCA2 gene, they're much more likely to die from the disease. It's important that more research is done in this area to ensure that this group is targeted effectively so cancer is picked up at an early stage and, more importantly, that they are given the most appropriate treatment."

Results from previous studies have shown that men with a faulty BRCA2 gene can be up to five times more likely than the general population to develop prostate cancer. Dr Steven Narod, the lead researcher, said that the new findings are important, as men with a faulty BRCA2 gene are not responding well to current treatments.

25th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics